Xynomic Pharmaceuticals
Recent Finacing
Series B
Recent Raise
Undisclosed
Xynomic Pharma is a clinical-stage oncology biopharmaceutical company developing HDAC inhibitor Abexinostat and pan-RAF inhibitor XP-102 through global monotherapy and combination pivotal trials and institutional collaborations.
Highlights
Focus Areas
Biopharma
Biotechnology
Medical
Oncology
Pharmaceutical
Recent Investors
Financials
1
Funding round
4
Investors